Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Terminated 4Active not recruiting 2Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 19Myeloid 9Lymphoid 8Thoracic 1Sarcoma 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 33Radiosurgery 23Radiotherapy 21Sunitinib 20pembrolizumab 18Gemcitabine 16Cisplatin 16Androgen Antagonists 15Nivolumab 14enzalutamide 13Goserelin 13Prednisone 12Leuprolide 12Blood Specimen Collection 12Abiraterone Acetate 12bicalutamide 11aldesleukin 11Surveys and Questionnaires 11Cyclophosphamide 11Gonadotropin-Releasing Hormone 10Bevacizumab 10Multiparametric Magnetic Resonance Imaging 9Carboplatin 9acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 8Triptorelin Pamoate 8Radiotherapy, Intensity-Modulated 8Filgrastim 8Epirubicin 8Chemotherapy, Adjuvant 8Brachytherapy 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Dasatinib × Genitourinary × Clear all
NCT01685125 2017-07-07

Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

University of Southern California

Phase 2 Unknown
96 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡